Novartis AG ADR buy melinda
Start price
30.07.17
/
50%
€77.06
Target price
20.09.17
€77.57
Performance (%)
0.91%
End price
20.09.17
€77.76
Summary
This prediction ended on 20.09.17 with a price of €77.76. During the runtime of the prediction for Novartis AG ADR the price only changed by 0.91%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novartis AG ADR | 1.230% | 1.230% | 30.000% | 44.953% |
| iShares Core DAX® | -1.875% | 2.861% | 18.863% | 63.672% |
| iShares Nasdaq 100 | -2.177% | 0.048% | 3.956% | 109.562% |
| iShares Nikkei 225® | -0.867% | 6.987% | 21.062% | 54.912% |
| iShares S&P 500 | -1.253% | 1.248% | 2.246% | 69.801% |
Comments by melinda for this prediction
In the thread Novartis AG ADR diskutieren
NOVARTIS
Novartis AG
Zykadia (sNDA)
FDA Entscheidung über Zykadia als First-Line - Behandlung von Patienten mit Krebs der Lunge metastasierendem nicht-kleinzelligen (NSCLC) , deren Tumoren sind anaplastic lymphatische Kinase (ALK) - positiv
2017.08.23
FDA genehmigt den erweiterten Einsatz von Zykadia 26, Mai 2017